VIDEO: Exploring SYMPLICITY’s failure, Part 2

WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to measure its effectiveness.

In Part 2 of our interview, Dr. Prakash Deedwania and Dr. George Bakris explore the options, and don’t miss the chance to talk about the controversial new hypertension guidelines.

[email protected]

On Twitter @mitchelzoler

WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to measure its effectiveness.

In Part 2 of our interview, Dr. Prakash Deedwania and Dr. George Bakris explore the options, and don’t miss the chance to talk about the controversial new hypertension guidelines.

[email protected]

On Twitter @mitchelzoler

WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to measure its effectiveness.

In Part 2 of our interview, Dr. Prakash Deedwania and Dr. George Bakris explore the options, and don’t miss the chance to talk about the controversial new hypertension guidelines.

[email protected]

On Twitter @mitchelzoler